Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions

Oncotarget

Volumn 5, Issue 20, 2014, Pages 9641-9649

  Sakai, Kazuko ^a   Kazama, Shinsuke ^b   Nagai, Yuzo ^b   Murono, Koji ^b   Tanaka, Toshiaki ^b   Ishihara, Soichiro ^b   Sunami, Eiji ^b   Tomida, Shuta ^a   Nishio, Kazuto ^a   Watanabe, Toshiaki ^b  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chemoradiation; Deep sequencing; Rectal cancer; RNA sequencing; TP53

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; DNA; PROTEIN P53; RNA; FOLINIC ACID; TEGAFUR; TP53 PROTEIN, HUMAN; URACIL;

APC GENE; ARTICLE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLONE; CONTROLLED STUDY; DNA SEQUENCE; DRUG RESPONSE; DRUG SENSITIVITY; FBXW7 GENE; GENE; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MINIMAL RESIDUAL DISEASE; MUTANT; PROTEIN EXPRESSION; RADIATION RESPONSE; RADIOSENSITIVITY; RECTUM CANCER; RNA SEQUENCE; TUMOR SUPPRESSOR GENE; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; BIOSYNTHESIS; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MUTATION; RECTAL NEOPLASMS; RETROSPECTIVE STUDY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; DNA, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; LEUCOVORIN; MUTATION; NEOADJUVANT THERAPY; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; TEGAFUR; TUMOR SUPPRESSOR PROTEIN P53; URACIL;

EID: 84923097689     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2438     Document Type: Article

References (29)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893-917.
2. Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, Dixon MF, Quirke P. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet. 1994; 344:707-11.
3. Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg. 2006; 93:1115-22.
4. Foster JD, Jones EL, Falk S, Cooper EJ, Francis NK. Timing of surgery after long-course neoadjuvant chemoradiotherapy for rectal cancer: a systematic review of the literature. Dis Colon Rectum. 2013; 56:921-30.
5. van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van de Velde CJ. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011; 12:575-82.
6. Salendo J, Spitzner M, Kramer F, Zhang X, Jo P, Wolff HA, Kitz J, Kaulfuss S, Beissbarth T, Dobbelstein M, Ghadimi M, Grade M, Gaedcke J. Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g. Radiother Oncol. 2013; 108:451-7.
7. Watanabe T, Kobunai T, Akiyoshi T, Matsuda K, Ishihara S, Nozawa K. Prediction of response to preoperative chemoradiotherapy in rectal cancer by using reverse transcriptase polymerase chain reaction analysis of four genes. Dis Colon Rectum. 2014; 57:23-31.
8. Tuch BB, Laborde RR, Xu X, Gu J, Chung CB, Monighetti CK, Stanley SJ, Olsen KD, Kasperbauer JL, Moore EJ, Broomer AJ, Tan R, Brzoska PM. Tumor transcriptome sequencing reveals allelic expression imbalances associated with copy number alterations. PLoS One. 2010; 5:e9317.
9. Wang Y, Li Y, Liu S, Shen W, Jiang B, Xu X, Xie Y. Study on the dynamic behavior of a DNA microarray. J Nanosci Nanotechnol. 2005; 5:1249-55.
10. Casneuf T, Van de Peer Y, Huber W. In situ analysis of cross-hybridisation on microarrays and the inference of expression correlation. BMC Bioinformatics. 2007; 8:461.
11. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009; 458:719-24.
12. Oshlack A, Robinson MD, Young MD. From RNA-seq reads to differential expression results. Genome Biol. 2010; 11:220.
13. Kleiman LB, Krebs AM, Kim SY, Hong TS, Haigis KM. Comparative Analysis of Radiosensitizers for K-RAS Mutant Rectal Cancers. PLoS One. 2013; 8:e82982.
14. Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, Ding H, Mao C, Tang JL. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis. Int J Cancer. 2013; 133:1914-25.
15. Murono K, Kawai K, Tsuno NH, Ishihara S, Yamaguchi H, Sunami E, Kitayama J, Watanabe T. Barium enema and CT volumetry for predicting pathologic response to preoperative chemoradiotherapy in rectal cancer patients. Dis Colon Rectum. 2014; 57:715-24.
16. Cheng G, Kong D, Hou X, Liang B, He M, Liang N, Ma S, Liu X. The tumor suppressor, p53, contributes to radiosensitivity of lung cancer cells by regulating autophagy and apoptosis. Cancer Biother Radiopharm. 2013; 28:153-9.
17. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991; 351:453-6.
18. Sandulache VC, Skinner HD, Ow TJ, Zhang A, Xia X, Luchak JM, Wong LJ, Pickering CR, Zhou G, Myers JN. Individualizing antimetabolic treatment strategies for head, neck squamous cell carcinoma based on TP53 mutational status. Cancer. 2012; 118:711-21.
19. Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, Fitzgerald AL, Giri U, Ang KK, Myers JN. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res. 2012; 18:290-300.
20. Williams JR, Zhang Y, Zhou H, Gridley DS, Koch CJ, Russell J, Slater JS, Little JB. A quantitative overview of radiosensitivity of human tumor cells across histological type and TP53 status. Int J Radiat Biol. 2008; 84:253-64.
21. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlbock M, Gnant M, Steger G, Jakesz R. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res. 2000; 6:50-6.
22. Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013; 19: 5777-87.
23. Grim JE. Fbxw7 hotspot mutations and human colon cancer: mechanistic insights from new mouse models. Gut. 2014; 63:707-9.
24. Mouradov D, Domingo E, Gibbs P, Jorissen RN, Li S, Soo PY, Lipton L, Desai J, Danielsen HE, Oukrif D, Novelli M, Yau C, Holmes CC. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am J Gastroenterol. 2013; 108:1785-93.
25. Matsumoto A, Onoyama I, Nakayama KI. Expression of mouse Fbxw7 isoforms is regulated in a cell cycle- or p53-dependent manner. Biochem Biophys Res Commun. 2006; 350:114-9.
26. Matsuoka S, Oike Y, Onoyama I, Iwama A, Arai F, Takubo K, Mashimo Y, Oguro H, Nitta E, Ito K, Miyamoto K, Yoshiwara H, Hosokawa K. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev. 2008; 22:986-91.
27. Onoyama I, Tsunematsu R, Matsumoto A, Kimura T, de Alboran IM, Nakayama K, Nakayama KI. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J Exp Med. 2007; 204:2875-88.
28. Yokobori T, Yokoyama Y, Mogi A, Endoh H, Altan B, Kosaka T, Yamaki E, Yajima T, Tomizawa K, Azuma Y, Onozato R, Miyazaki T, Tanaka S. FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs. Mol Cancer Res. 2014; 12:32-7.
29. Lesko AC, Goss KH, Prosperi JR. Exploiting APC function as a novel cancer therapy. Curr Drug Targets. 2014; 15: 90-102.